OMERS ADMINISTRATION Corp Buys Shares of 9,380 IQVIA Holdings Inc. $IQV

OMERS ADMINISTRATION Corp purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, Holdings Channel reports. The fund purchased 9,380 shares of the medical research company’s stock, valued at approximately $1,812,000.

Other large investors also recently modified their holdings of the company. Osmosis Investment Management UK Ltd bought a new stake in shares of IQVIA during the second quarter valued at about $895,000. Sanctuary Advisors LLC acquired a new position in IQVIA during the 2nd quarter valued at about $1,643,000. Globeflex Capital L P bought a new stake in shares of IQVIA during the 2nd quarter worth about $271,000. True Freedom Investing LLC acquired a new stake in shares of IQVIA in the 2nd quarter worth approximately $3,803,000. Finally, Clear Harbor Asset Management LLC bought a new position in shares of IQVIA in the second quarter valued at approximately $3,714,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Up 0.8%

Shares of NYSE:IQV opened at $261.57 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.22 and a beta of 1.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $262.51. The company has a 50 day moving average price of $218.41 and a 200 day moving average price of $188.59.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 12,913 shares of company stock worth $3,098,793. Company insiders own 1.70% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Stifel Nicolaus increased their price target on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. HSBC restated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Finally, Robert W. Baird raised their target price on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.